Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry

Wang, Bing‐Yen; Huang, Jing‐Yang; Cheng, Ching-Yuan; Lin, Ching-Hsiung; Ko, Jiunn‐Liang; Liaw, Yung‐Po

doi:10.1097/jto.0b013e31829ceba4

Cited by 106 publications

(90 citation statements)

References 39 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[21][22][23][24] A large population-based Taiwan cancer registry demonstrated that women with lung cancer had a better median and 5-year survival. 25 Lungscape is the first large series reporting on lung cancer surgical outcome measured not only by OS but also by RFS and TTR and presenting multivariate analysis including most of the significant clinical and pathological prognostic parameters reported to date. As tissue from all patients has been preserved locally and is available for detailed molecular investigations, Lungscape provides an excellent basis to evaluate the influence of molecular parameters on the disease outcome after radical resection, in addition to providing an overview of the molecular landscape of stage I to III NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

Peters

Weder

Dafni

et al. 2014

Journal of Thoracic Oncology

View full text Add to dashboard Cite

The aim of this report is to present the results from Lungscape, the first large series reporting on NSCLC surgical outcome measured not only by OS but also by RFS and time to relapse and including multivariate analysis by significant clinical and pathological prognostic parameters. As tissue from all patients is preserved locally and is available for detailed molecular investigations, Lungscape provides an excellent basis to evaluate the influence of molecular parameters on the disease outcome after radical resection, besides providing an overview of the molecular landscape of stage I to III NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

Peters

Weder

Dafni

et al. 2014

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…In 2012, lung cancer was responsible for 1.6 million deaths, amounting to about 20% of all cancer‐related deaths (International Agency for Research on Cancer, 2014). The 5‐year survival rates for lung cancer in 2005–2009 ranged from 15% to 20% in most countries (Cheng et al., 2016; Wang et al., 2013). Non‐small cell lung cancer (NSCLC) is the most common histological type, comprising approximately 80%–85% of cases (Herbst, Heymach, & Lippman, 2008; Reck, Heigener, Mok, Soria, & Rabe, 2013).…”

Section: Introductionmentioning

confidence: 99%

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

et al. 2017

View full text Add to dashboard Cite

The aim of this multinational retrospective cohort study, conducted at academic and community oncology centres, was to describe real‐world treatment patterns for patients with a confirmed diagnosis of advanced/metastatic (stage IIIB/IV) non‐small cell lung cancer (NSCLC) who initiated first‐line systemic therapy from January 2011 through June 2014. The study included 1265 patients in Italy, Spain, Germany, Australia, Korea, Taiwan and Brazil. The proportion of patients with squamous versus non‐squamous NSCLC was approximately 20% versus 75%, and associated patient demographic characteristics were similar in all countries, excepting race. Patients with squamous NSCLC were predominantly male and current/ex‐smokers. Biomarker tests were performed for the majority of patients with non‐squamous NSCLC, ranging from 54% (Brazil) to 91% in Taiwan, where, of those tested, 68% with non‐squamous NSCLC had positive epidermal growth factor receptor (EGFR)‐mutation status; in other countries the EGFR‐positive percentages ranged from 17% (Spain/Brazil) to 40% (Korea). Platinum‐based regimens were the most common first‐line therapy in all countries except Taiwan, where gefitinib was the most common first‐line agent. Median overall survival ranged from 9.3 months (Brazil) to 25.5 months (Taiwan). The diagnostic and treatment patterns recorded in this study were heterogeneous but largely in line with NSCLC guidelines during the study period.

show abstract

“…17 Patients with shorter survival were always with worse differentiated pathogenesis. So, it's essential to investigate the biological indication of MAC30 on tumor differentiation, which affects clinical therapies and survival of patients with NSCLC.…”

Section: Mac30 Expression On Prognosis Of Tumor Differentiationmentioning

confidence: 99%

The Prognostic Effect of MAC30 Expression on Patients With Non–Small Cell Lung Cancer Receiving Adjuvant Chemotherapy

Ding

Gui

Lin

et al. 2016

Technol Cancer Res Treat

View full text Add to dashboard Cite

The purpose of this study was to examine the MAC30 expression in non-small cell lung cancer and to evaluate its prognostic value on therapeutic response in patients with non-small cell lung cancer receiving postoperative chemotherapy. Among a total of 218 retrospective Chinese patients with non-small cell lung cancer, 164 patients receiving adjuvant chemotherapy were enrolled in this study. Real-time polymerase chain reaction was performed to confirm the expression of MAC30 messenger RNA in 32 cases of non-small cell lung cancer tumors with the corresponding nontumor lung tissues. The MAC30 protein expression in all specimens was analyzed by immunohistochemical staining. Moreover, we assessed the correlation of MAC30 expression with clinicopathological features, therapeutic response, and survival of patients. Here, we observed the increased expression of MAC30 messenger RNA in patients with nonsmall cell lung cancer compared to those in control samples. The overexpression of MAC30 was strongly associated with poor tumor differentiation, high tumor-node-metastasis stage, and lymph node metastasis. In addition, we observed that patients with increased MAC30 expression showed gloomy overall survival and disease-free survival. A multivariate analysis explicated that higher MAC30 expression was a valuable independent prognostic factor of poorer tumor differentiation, shorter overall survival, and disease-free survival in patients receiving chemotherapy. MAC30 could be a useful biomarker of tumor differentiation and outcome of patients with non-small cell lung cancer. Overexpression of MAC30 predicts a worse tumor differentiated stage and prognosis in patients with non-small cell lung cancer receiving adjuvant chemotherapy.

show abstract

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry

Abstract: In additional to tumor-nodes-metastasis (TNM) staging system, patient sex and age, tumor location, cell type, and differentiation were independent prognostic factors. We recommend incorporation of these factors to subclassify lung cancer patients.

Cited by 106 publications

References 39 publications

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study

The Prognostic Effect of MAC30 Expression on Patients With Non–Small Cell Lung Cancer Receiving Adjuvant Chemotherapy

Contact Info

Product

Resources

About